Research programme: transdermal therapeutics - Apricus Biosciences

Drug Profile

Research programme: transdermal therapeutics - Apricus Biosciences

Alternative Names: Calcipotriene/betamethasone - Apricus Biosciences; Calcipotriol/betamethasone dipropionate - NexMed; PsoriaVa

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences
  • Class
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 21 Sep 2016 Discontinued - Preclinical for Psoriasis in USA (Topical)
  • 01 Apr 2011 Preclinical development is ongoing in USA
  • 10 Sep 2010 NexMed is now called Apricus Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top